- Ticker
- ABOS
- Price
- 5.62
- Stock movement up
- +0.01 (0.09%)
- Company name
- Acumen Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 229.80M
- Ent value
- 78.87M
- Price/Sales
- -
- Price/Book
- 1.17
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -14.01%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-09-08
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head-Investor RelationsDan O'Connell - Chief...
August 11, 2023
iO Charts is a Seeking Alpha partner
The following slide deck was published by Acumen Pharmaceuticals, Inc.
August 9, 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABOS does not pay dividends or no data was received
Loading...
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.17 |
| EV to Sales | - |
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
August 8, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 19, 2023
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 40.93M |
| EPS (TTM) | -0.95 |
| FCF per share (TTM) | -0.69 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -39.40M |
| Net income (TTM) | -38.34M |
| EPS (TTM) | -0.95 |
| EPS (1y forward) | -1.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 157.54M |
| Net receivables | 121.00K |
| Total current assets | 202.56M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 203.26M |
| Accounts payable | 2.08M |
| Short/Current long term debt | 133.00K |
| Total current liabilities | 6.61M |
| Total liabilities | 6.61M |
| Shareholder's equity | 196.65M |
| Net tangible assets | 196.65M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.59M |
| Capital expenditures (TTM) | 158.00K |
| Free cash flow (TTM) | -27.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -19.50% |
| Return on Assets | -18.86% |
| Return on Invested Capital | -19.48% |
| Cash Return on Invested Capital | -14.10% |
Loading...
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.61 |
| Daily high | 5.66 |
| Daily low | 5.52 |
| Daily Volume | 158K |
| All-time high | 20.28 |
| 1y analyst estimate | 15.83 |
| Beta | - |
| EPS (TTM) | -0.95 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 Nov 2023 |
Downside potential
Loading...
Downside potential data
| ABOS | S&P500 | |
| Current price drop from All-time high | -72.31% | -6.74% |
| Highest price drop | -84.81% | -56.47% |
| Date of highest drop | 11 May 2022 | 9 Mar 2009 |
| Avg drop from high | -63.73% | -11.49% |
| Avg time to new high | 551 days | 13 days |
| Max time to new high | 550 days | 1805 days |
Acumen reported positive topline results from its phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early Alzheimer's Disease. Read more here.
July 18, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
229.80M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual AAIC. Check out our recommendation on ABOS stock.
July 13, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 9, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
June 13, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head IRDaniel O'Connell - President and CEOEric...
May 14, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
May 9, 2023
The following slide deck was published by Acumen Pharmaceuticals, Inc.
March 27, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head IRDaniel O'Connell - President and Chief...
March 27, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
March 27, 2023
Acumen Pharmaceuticals is an early-stage developmental concern focusing on development treatments for Alzheimer's. Click here to read ABOS' investment analysis.
December 26, 2022
Acumen Pharmaceuticals (ABOS) Q3 2022 Earnings Conference Call Nov 14, 2022 04:30 PM ET
November 15, 2022
iO Charts is a Seeking Alpha partnerNext page